Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Arghya Ray, PhD, Yan Song, PhD, Ting DU, PhD, Clifton C. Mo, MD, Arturo Olguin, Janice Chen, PhD, Christopher Brooks, PhD, Tariq I. Mughal, MD FRCP, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141571

Published: 2020

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Aishwarya Krishnan, Maria Pagane, Mikhail Roshal, MD PhD, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 2967.

https://doi.org/10.1182/blood-2019-129397

Published: 2019

Journal Articles

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, Thomas G. Martin, III, MD, Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD, Claudia E. Paba-Prada, MD

Blood (2019) 134 (Supplement_1): 3145.

https://doi.org/10.1182/blood-2019-130410

Published: 2019

Journal Articles

Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML)

Aishwarya Krishnan, Bing Li, MD, Maria Pagane, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2018) 132 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2018-99-120035

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Gary J. Schiller, MD, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Arturo Olguin, Christopher Brooks, PhD, Vanessa Dunn, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2018) 132 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2018-99-119201

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

Mrinal M. Patnaik, MD MBBS, Haris Ali, MD, Vikas Gupta, MD FRCP, FRCPath, Gary J. Schiller, MD, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Arturo Olguin, Christopher Brooks, PhD, Vanessa Dunn, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2018) 132 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2018-99-119302

Published: 2018

Journal Articles

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2018) 132 (Supplement 1): 765.

https://doi.org/10.1182/blood-2018-99-118966

Published: 2018

Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2017) 130 (Supplement 1): 1298.

https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Blood (2017) 130 (Supplement 1): 2583.

https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Mrinal M. Patnaik, MDMBBS, Vikas Gupta, MD PhD, Gary J. Schiller, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Animesh Pardanani, MBBS PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2017) 130 (Supplement 1): 2908.

https://doi.org/10.1182/blood.V130.Suppl_1.2908.2908

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey Zonder, MD, Thomas G. Martin, III, MD, Emma C. Scott, MD, Janice Chen, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Claudia E. Paba-Prada, MD

Blood (2016) 128 (22): 5696.

https://doi.org/10.1182/blood.V128.22.5696.5696

Published: 2016

Journal Articles

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Janice Chen, PhD, Shay Shemesh, MA, Peter McDonald, Christopher L. Brooks, PhD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 342.

https://doi.org/10.1182/blood.V128.22.342.342

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Blood (2016) 128 (22): 215.

https://doi.org/10.1182/blood.V128.22.215.215

Published: 2016

Journal Articles

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Deepika Sharma Das, PhD, Vincent Macri, MA, Janice Chen, PhD, Claudia Paba-Praba, Paul G. Richardson, MD, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4463.

https://doi.org/10.1182/blood.V128.22.4463.4463

Published: 2016

Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

John Gionco, Janice Chen, PhD, Ross Lindsay, PhD, Vince Macri, M.A., Christopher L. Brooks, PhD

Blood (2016) 128 (22): 4724.

https://doi.org/10.1182/blood.V128.22.4724.4724

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Blood (2016) 128 (22): 4245.

https://doi.org/10.1182/blood.V128.22.4245.4245

Published: 2016

Journal Articles

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Janice Chen, PhD, Christopher L. Brooks, PhD, Peter McDonald, Jonathan D. Schwartz, MD, Rebecca S. Schneider, Keiichi Sakakibara, PhD, Naoya Saito, PhD, Takuji Sato, MSc, Takumi Kawabe, MD PhD, Eric K. Rowinsky, MD

Blood (2015) 126 (23): 4433.

https://doi.org/10.1182/blood.V126.23.4433.4433

Published: 2015

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Amanda L Christie, B.S., Yvonne Li, PhD, Katsuhiro Togami, MD, Mahmoud Ghandi, PhD, Alexandra N. Christodoulou, M.S., Kevin Buczkowski, Fanny Angelot-Delettre, PhD, Sabeha Biichle, Janice Chen, PhD, Christopher L. Brooks, PhD, David M. Weinstock, MD, Francine Garnache-Ottou, PhD, Peter S Hammerman, MD PhD, Andrew A Lane, MD PhD

Blood (2015) 126 (23): 3797.

https://doi.org/10.1182/blood.V126.23.3797.3797

Published: 2015

Journal Articles

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Janice Chen, PhD, Vince Macri, MA, Pedro Herrera, MA, Christopher Brooks, PhD, Eric Rowinsky, MD

Blood (2014) 124 (21): 4500.

https://doi.org/10.1182/blood.V124.21.4500.4500

Published: 2014

NARROW

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML)

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only